A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster

BMC Infectious Diseases

Wei-Pin Chang⁵  Wei-Chiao Chang⁴  Ming-Yii Huang¹  Chun-Yi Lin⁵  Yi-Ting Lin²  Ping-Hsun Wu³ 

[1] Department of Radiation Oncology, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei, Taiwan;Department of Healthcare Management, Yuanpei University of Medical Technology, Hsinchu, Taiwan

关键词: Taiwan National Health Insurance Research Database;    Population-based study;    Herpes zoster;    Heart failure;   

Others  :  1089864
DOI  :  10.1186/s12879-015-0747-9

 received in 2013-11-15, accepted in 2015-01-06,  发布年份 2015

【 摘 要 】

Background

The association between heart failure (HF) and herpes zoster has rarely been studied. We investigated the hypothesis that HF may increase the risk of herpes zoster in Taiwan using a nationwide Taiwanese population-based claims database.

Method

Our study cohort consisted of patients who received a diagnosis of HF in 2001 ~ 2009 (N = 4785). For a comparison cohort, three age- and gender-matched control patients for every patient in the study cohort were selected using random sampling (N = 14,355). All subjects were tracked for 1 year from the date of cohort entry to identify whether or not they had developed herpes zoster. Cox proportional-hazard regressions were performed to evaluate 1-year herpes zoster-free survival rates.

Results

The main finding of this study was that patients with HF seemed to be at an increased risk of developing herpes zoster. Of the total patients, 211 patients developed herpes zoster during the 1-year follow-up period, among whom 83 were HF patients and 128 were in the comparison cohort. The adjusted hazard ratio (AHR) of herpes zoster in patients with HF was higher (AHR: 2.07; 95% confidence interval (CI): 1.54 ~ 2.78; p < 0.001) than that of the controls during the 1-year follow-up. Our study also investigated whether HF is a gender-dependent risk factor for herpes zoster. We found that male patients with HF had an increased risk of developing herpes zoster (AHR: 2.30 95% CI: 1.51 ~ 3.50; p < 0.001).

Conclusions

The findings of our population-based study suggest that patients with HF may have an increased risk of herpes zoster. These health associations should be taken into consideration, and further studies should focused on the cost-effectiveness of the herpes zoster vaccine should be designed for HF patients.

【 授权许可】

   
2015 Wu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, Chen CC, Lee DD, Chang YT, Wang WJ, et al.: Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009, 89(6):612-6.
• [2]Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ: Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000, 342(9):635-45.
• [3]Lin HC, Chien CW, Ho JD: Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology 2010, 74(10):792-7.
• [4]Kang JH, Ho JD, Chen YH, Lin HC: Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009, 40(11):3443-8.
• [5]Ho JD, Xirasagar S, Lin HC: Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study. Ophthalmology 2011, 118(6):1076-81.
• [6]Chiu HF, Chen BK, Yang CY: Herpes zoster and subsequent risk of cancer: a population-based study. J Epidemiol 2013, 23(3):205-10.
• [7]Wareham DW, Breuer J: Herpes zoster. BMJ 2007, 334(7605):1211-5.
• [8]Liesegang TJ: Herpes zoster virus infection. Curr Opin Opthalmol 2004, 15(6):531-6.
• [9]Bowsher D: The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999, 3(4):335-42.
• [10]Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127(2):305-14.
• [11]Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, Chang LY: Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010, 28(5):1217-20.
• [12]Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. Arch Intern Med 1995, 155(15):1605-9.
• [13]Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proceedings Mayo Clinic 2007, 82(11):1341-9.
• [14]Schmader K, George LK, Burchett BM, Pieper CF: Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis 1998, 178(Suppl 1):S67-70.
• [15]Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V: Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008, 36(3):226-30.
• [16]Arvin AM: Varicella-zoster virus. Clin Microbiol Rev 1996, 9(3):361-81.
• [17]Gilden DH, Cohrs RJ, Mahalingam R: Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 2003, 16(3):243-58.
• [18]Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA: Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 2008, 26(3):675-97. viii
• [19]Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA: The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57(8):1431-8.
• [20]Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004, 4(1):26-33.
• [21]Wolfe F, Michaud K, Chakravarty EF: Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006, 45(11):1370-5.
• [22]McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009, 48(10):1364-71.
• [23]Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, et al.: Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005, 118(12):1416.
• [24]Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY: Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo) 2011, 66(7):1177-82.
• [25]Yang YW, Chen YH, Wang KH, Wang CY, Lin HW: Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. Can Med Assoc 2011, 183(5):E275-80.
• [26]Hope-Simpson RE: The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis. Proc R Soc Med 1965, 58:9-20.
• [27]Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, et al.: Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003, 188(9):1336-44.
• [28]Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292(3):344-50.
• [29]Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi N, Satterfield S, Bauer DC, Bibbins-Domingo K, et al.: Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med 2009, 169(7):708-15.
• [30]Capron J, Steichen O: Disseminated zoster in an elderly patient. Infection 2009, 37(2):179-80.
• [31]Hata A, Kuniyoshi M, Ohkusa Y: Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 2011, 39(6):537-44.
• [32]Kiecolt-Glaser JK, Glaser R: Psychoneuroimmunology and health consequences: data and shared mechanisms. Psychosom Med 1995, 57(3):269-74.
• [33]Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, Levin MJ, Hayward AR, Oxman MN: Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis 1998, 178(Suppl 1):S104-8.
• [34]Moser DK, Worster PL: Effect of psychosocial factors on physiologic outcomes in patients with heart failure. J Cardiovasc Nurs 2000, 14(4):106-15.
• [35]Piano MR, Kim SD, Jarvis C: Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention. J Cardiovasc Nurs 2000, 14(4):1-23. quiz 119–120
• [36]Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR: Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 2004, 93(8):1007-11.
• [37]Odom CI, Gaston DC, Markert JM, Cassady KA: Human herpesviridae methods of natural killer cell evasion. Advance Virol 2012, 2012:359869.
• [38]Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P: Health care utilization and cost burden of herpes zoster in a community population. Mayo Clinic Proceedings Mayo Clinic 2009, 84(9):787-94.
• [39]Cotton SJ, Belcher J, Rose P, Jagadeesan KS, Neal RD: The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer 2013, 108(3):721-6.
• [40]Iglar K, Kopp A, Glazier RH: Herpes zoster as a marker of underlying malignancy. Open J Med 2013, 7(2):e68-73.
• [41]Buntinx F, Wachana R, Bartholomeeusen S, Sweldens K, Geys H: Is herpes zoster a marker for occult or subsequent malignancy? Br J Gen Pract 2005, 55(511):102-7.
• [42]Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-84.
• [43]Svanstrom H, Pasternak B, Hviid A: Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012, 307(14):1506-12.